Detailed information for compound 433428

Basic information

Technical information
  • TDR Targets ID: 433428
  • Name: N-[3-hydroxy-4-[4-(2-methoxyphenyl)piperazin- 1-yl]butyl]-9H-fluorene-2-carboxamide
  • MW: 471.591 | Formula: C29H33N3O3
  • H donors: 2 H acceptors: 2 LogP: 4.17 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1ccccc1N1CCN(CC1)CC(CCNC(=O)c1ccc2c(c1)Cc1c2cccc1)O
  • InChi: 1S/C29H33N3O3/c1-35-28-9-5-4-8-27(28)32-16-14-31(15-17-32)20-24(33)12-13-30-29(34)22-10-11-26-23(19-22)18-21-6-2-3-7-25(21)26/h2-11,19,24,33H,12-18,20H2,1H3,(H,30,34)
  • InChiKey: TUZMIWVHPWQEBK-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[3-hydroxy-4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-9H-fluorene-2-carboxamide
  • N-[3-hydroxy-4-[4-(2-methoxyphenyl)piperazino]butyl]-9H-fluorene-2-carboxamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens dopamine receptor D4 Starlite/ChEMBL References
Homo sapiens dopamine receptor D2 Starlite/ChEMBL References
Homo sapiens dopamine receptor D3 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi hypothetical protein dopamine receptor D3 400 aa 392 aa 19.9 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Loa Loa (eye worm) phosphatidylinositol 3 0.0426 0.0463 1
Trypanosoma cruzi Phosphatidylinositol 3-kinase tor2 0.0426 0.0463 0.15
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma cruzi phosphatidylinositol 3-related kinase, putative 0.0426 0.0463 0.15
Trypanosoma cruzi phosphatidylinositol kinase related protein, putative 0.0346 0.0265 0.086
Echinococcus multilocularis serine protein kinase ATM 0.0346 0.0265 0.0265
Trypanosoma brucei phosphatidylinositol 4-kinase, putative 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma brucei target of rapamycin kinase 3, putative 0.0426 0.0463 1
Trypanosoma cruzi Phosphatidylinositol 3-kinase tor1 0.0426 0.0463 0.15
Trypanosoma brucei Phosphatidylinositol 3-kinase tor1 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Echinococcus multilocularis FKBP12 rapamycin complex associated protein 0.0426 0.0463 0.0463
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Loa Loa (eye worm) hypothetical protein 0.0264 0.0061 0.1318
Echinococcus multilocularis DNA dependent protein kinase catalytic subunit 0.4248 1 1
Entamoeba histolytica hypothetical protein 0.0346 0.0265 0.5731
Brugia malayi Phosphatidylinositol 3- and 4-kinase family protein 0.0426 0.0463 1
Schistosoma mansoni ataxia telangiectasia mutated (atm) 0.0346 0.0265 0.5731
Echinococcus granulosus phosphatidylinositol 3 and 4 kinase 0.0426 0.0463 0.0463
Entamoeba histolytica FKBP-rapamycin associated protein (FRAP), putative 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Leishmania major hypothetical protein, conserved 0.1559 0.329 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma brucei phosphatidylinositol kinase related protein, putative 0.0346 0.0265 0.4991
Echinococcus granulosus serine protein kinase ATM 0.0346 0.0265 0.0265
Echinococcus granulosus FKBP12 rapamycin complex associated protein 0.0426 0.0463 0.0463
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Entamoeba histolytica phosphatidylinositol3-kinaseTor2, putative 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma cruzi phosphatidylinositol 3-related kinase, putative 0.0426 0.0463 0.15
Toxoplasma gondii target of rapamycin (TOR), putative 0.0426 0.0463 1
Trichomonas vaginalis conserved hypothetical protein 0.0267 0.0068 0.1478
Brugia malayi Phosphatidylinositol 3- and 4-kinase family protein 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma cruzi phosphatidylinositol kinase related protein, putative 0.0264 0.0061 0.0198
Trypanosoma brucei phosphatidylinositol 3-related kinase, putative 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Giardia lamblia GTOR 0.0426 0.0463 0.5
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Toxoplasma gondii FATC domain-containing protein 0.0346 0.0265 0.4991
Schistosoma mansoni phosphatidylinositol 3-and 4-kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma cruzi hypothetical protein, conserved 0.1477 0.3086 1
Loa Loa (eye worm) hypothetical protein 0.0267 0.0068 0.1478
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Brugia malayi Phosphatidylinositol 3- and 4-kinase family protein 0.0346 0.0265 0.5731
Trichomonas vaginalis PIKK family atypical protein kinase 0.0267 0.0068 0.1478
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Loa Loa (eye worm) phosphatidylinositol 3 0.0426 0.0463 1
Schistosoma mansoni ataxia telangiectasia mutated (atm)-related 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma cruzi target of rapamycin kinase 3 0.0426 0.0463 0.15
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0346 0.0265 0.5731
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trypanosoma brucei phosphatidylinositol 3-kinase, putative 0.0426 0.0463 1
Echinococcus multilocularis phosphatidylinositol 3 and 4 kinase 0.0426 0.0463 0.0463
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1
Trichomonas vaginalis PIKK family atypical protein kinase 0.0426 0.0463 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 3.9 nM BindingDB_Patents: Binding Assay. Methods for performing in vitro dopamine receptor binding studies are described in Huang et al. J. Med. Chem. 44:1815-1826 (2001) and Luedtke et al. Synapse 38:438-439 (2000). These papers describe radioactively labeled dopamine receptor selective ligands binding with picomolar affinity and nonselectivity to D2 and D3 dopamine receptors expressed in Sf9 and HEK 293 cells. 125I-IABN binds with 7- to 10-fold lower affinity to human D4.4 dopamine receptors expressed in HEK 293 cells. Dissociation constants (Kd) calculated from kinetic experiments were found to be in agreement with equilibrium Kd values obtained from saturation binding studies. Saturation plots of the binding of 125I-IABN with rat caudate membrane preparations were monophasic and exhibited low nonspecific binding. ChEMBL. No reference
IC50 (binding) = 3.9 nM BindingDB_Patents: Binding Assay. Methods for performing in vitro dopamine receptor binding studies are described in Huang et al. J. Med. Chem. 44:1815-1826 (2001) and Luedtke et al. Synapse 38:438-439 (2000). These papers describe radioactively labeled dopamine receptor selective ligands binding with picomolar affinity and nonselectivity to D2 and D3 dopamine receptors expressed in Sf9 and HEK 293 cells. 125I-IABN binds with 7- to 10-fold lower affinity to human D4.4 dopamine receptors expressed in HEK 293 cells. Dissociation constants (Kd) calculated from kinetic experiments were found to be in agreement with equilibrium Kd values obtained from saturation binding studies. Saturation plots of the binding of 125I-IABN with rat caudate membrane preparations were monophasic and exhibited low nonspecific binding. ChEMBL. No reference
Ki (binding) = 1.8 nM Displacement of [125I]IABN from human dopamine D3 receptor expressed in HEK293 cells ChEMBL. 17672446
Ki (binding) = 1.8 nM Displacement of [125I]IABN from human dopamine D3 receptor expressed in HEK293 cells ChEMBL. 17672446
Ki (binding) = 1.8 nM BindingDB_Patents: Binding Assay. Methods for performing in vitro dopamine receptor binding studies are described in Huang et al. J. Med. Chem. 44:1815-1826 (2001) and Luedtke et al. Synapse 38:438-439 (2000). These papers describe radioactively labeled dopamine receptor selective ligands binding with picomolar affinity and nonselectivity to D2 and D3 dopamine receptors expressed in Sf9 and HEK 293 cells. 125I-IABN binds with 7- to 10-fold lower affinity to human D4.4 dopamine receptors expressed in HEK 293 cells. Dissociation constants (Kd) calculated from kinetic experiments were found to be in agreement with equilibrium Kd values obtained from saturation binding studies. Saturation plots of the binding of 125I-IABN with rat caudate membrane preparations were monophasic and exhibited low nonspecific binding. ChEMBL. No reference
Ki (binding) = 1.8 nM BindingDB_Patents: Binding Assay. Methods for performing in vitro dopamine receptor binding studies are described in Huang et al. J. Med. Chem. 44:1815-1826 (2001) and Luedtke et al. Synapse 38:438-439 (2000). These papers describe radioactively labeled dopamine receptor selective ligands binding with picomolar affinity and nonselectivity to D2 and D3 dopamine receptors expressed in Sf9 and HEK 293 cells. 125I-IABN binds with 7- to 10-fold lower affinity to human D4.4 dopamine receptors expressed in HEK 293 cells. Dissociation constants (Kd) calculated from kinetic experiments were found to be in agreement with equilibrium Kd values obtained from saturation binding studies. Saturation plots of the binding of 125I-IABN with rat caudate membrane preparations were monophasic and exhibited low nonspecific binding. ChEMBL. No reference
Ki (binding) = 249 nM Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells ChEMBL. 17672446
Ki (binding) = 249 nM Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells ChEMBL. 17672446
Ki (binding) = 1230 nM Displacement of [125I]IABN from human dopamine D4 receptor expressed in HEK293 cells ChEMBL. 17672446
Ki (binding) = 1230 nM Displacement of [125I]IABN from human dopamine D4 receptor expressed in HEK293 cells ChEMBL. 17672446
Ratio Ki (binding) = 138 Selectivity for human dopamine D3 receptor over human dopamine D2 receptor ChEMBL. 17672446
Ratio Ki (binding) = 683 Selectivity for human dopamine D3 receptor over human dopamine D4 receptor ChEMBL. 17672446

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.